• darkblurbg

    TARGETING THE UNDERLYING

    CAUSES OF DIABETES

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

Calendar

 Dates for financial information and other events
June 26, 2019
Quarterly Report III
Quarterly Report 3 2018/2019
August 28 − August 29, 2019
LSX Nordic Congress
Stockholm, Sweden
October 2, 2019
Year-End Report
Year-End Report 2018/2019

We are seeing increased international visibility highlighting the work we are doing.

Ulf Hannelius
President and CEO, Diamyd Medical AB

THE COMPANY

Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development
The share is listed on Nasdaq Stockholm First North (ticker: DMYD B)


Read More
  • Diabetes

    10-20% of the more than 400 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.

  • Products

    The antigen-specific immunotherapy Diamyd® and the regenerative and immunomodulatory therapy Remygen® are two novel disease-modifying drugs in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.

  • Clinical Trials

    The efficacy of intralymphatic administration of Diamyd® on preserving the insulin producing ability in type 1 diabetes is being confirmed in the Phase IIb trial DIAGNODE-2. The safety and efficacy of Remygen® on stimulating growth of insulin producing cells in type 1 diabetes is being evaluated for the first time in the Phase I/II trial ReGenerate-1.